Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer | Zendy

Sung Jun | Zendy; Oluwadamilola T. Oladeru | Zendy; Joseph A. Miccio | Zendy; Austin J. Iovoli | Zendy; Gregory M. Hermann | Zendy; Anurag K. Singh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer

Author(s) -

Sung Jun,

Oluwadamilola T. Oladeru,

Joseph A. Miccio,

Austin J. Iovoli,

Gregory M. Hermann,

Anurag K. Singh

Publication year - 2019

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2019.9126

Subject(s) - medicine , interquartile range , adjuvant therapy , hazard ratio , pancreatic cancer , cohort , adjuvant , stage (stratigraphy) , proportional hazards model , cancer , oncology , retrospective cohort study , surgery , confidence interval , paleontology , biology

Key Points Question Is the timing of adjuvant therapy in resected pancreatic cancer associated with better survival? Findings This cohort study of 7548 patients with stage I to II pancreatic cancer in the National Cancer Database suggested improved survival when adjuvant therapy was initiated 28 to 59 days after surgery. Patients who recovered slowly from surgery still benefited from delayed adjuvant therapy initiated more than 12 weeks after the procedure compared with patients who received surgery alone. Meaning Shared decision-making between clinicians and patients is needed to individualize when to initiate adjuvant therapy based on patients’ postoperative recovery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research